TREE NEWS reports: Chinese innovative drug and CRO concept stocks rallied on Thursday, with Sino Biological touching the 20% daily limit up. Shandong Xinhua Pharmaceutical and Harbin Pharmaceutical Group had each posted two consecutive limit-ups, while Baihua Pharmaceutical, CanSino Biologics and Wanbang Pharmaceutical gained more than 6%.
China Innovative Drug and CRO Stocks Surge; Sino Biological Hits 20% Limit Up
AI take
The breadth of the move — spanning CRO services, innovative biologics and traditional pharma — suggests a sector-wide re-rating rather than a single catalyst. That matters for a market where these names have been sensitive to policy and funding cycles. The open question is whether the rally broadens further or concentrates in a few limit-up leaders.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
14m ago
Shenzhen Component, ChiNext turn positive as over 1,700 A-shares rise
41m ago
Hang Seng Tech Index Falls 2% Intraday; Alibaba Down Over 5%, Baidu Over 6%
1h ago
Chinese chip stocks rebound; Weitest up over 10%, Hua Hong up over 7%
1h ago
ChiNext Index Drops Over 1% as Nearly 4,200 A-Shares Fall
1h ago
CSI Convertible Bond Index opens down 0.02%
1h ago
China Game, AI Comic-Drama Stocks Fall at Open; Dianguang, Dasheng, Wentou Hit Limit Down